Department of Paediatrics & Adolescent Medicine, Queen Elizabeth Hospital, 30 Gascoigne Road, Kowloon, Hong Kong, China
WKY Chan ( 陳桂如 ) MRCP(UK), FHKAM, FHKCPaed
KW Lee ( 李國偉 ) MRCP, FHKAM, FHKCPaed
Department of Paediatrics & Adolescent Medicine, United Christian Hospital, 130 Hip Wo Street, Kwun Tong, Kowloon, Hong Kong, China
SY Chan ( 陳笑圓 ) MRCP, FHKAM, FHKCPaed
Department of Paediatrics & Adolescent Medicine, Queen Mary Hospital, Pokfulam Road, Hong Kong, China
W Chiu ( 趙永 ) MRCP, FHKAM, FHKCPaed
Department of Paediatrics & Adolescent Medicine, Tuen Mun Hospital, Tsing Chung Koon Road, Tuen Mun, N.T., Hong Kong, China
KW Fong ( 方國華 ) MBBS, MRCP(UK)
SN Wong ( 黃錫年 ) MRCP, FHKAM, FHKCPaed
Department of Paediatrics & Adolescent Medicine, Princess Margaret Hospital, 2-10 Princess Margaret Hospital Road, Lai Chi Kok, Kowloon, Hong Kong, China
NKC Tse ( 謝紀超 ) MRCP, FHKAM, FHKCPaed
Department of Paediatrics & Adolescent Medicine, Caritas Medical Center, Sham Shui Po, Kowloon, Hong Kong, China
PS Yeung ( 楊霸成 ) MRCP, FHKAM, FHKCPaed
Correspondence to: Dr WKY Chan
Received January 16, 2003
Henoch-Schönlein purpura (HSP) is a common vasculitic disease in children. Renal involvement in HSP is not uncommon and accounts for major morbidity. There are a lot of controversies in the management of patients with Henoch-Schönlein nephritis. After reviewing the literatures, our group conclude that (a) The presenting renal histology, which reveals the severity of kidney damage, is by far the most useful, although not entirely reliable prognosticator. (b) Patients with minor urinary abnormalities at presentation do not need any form of intervention, however follow up for subsequent renal impairment may be necessary. (c) Patients with moderate renal involvement may warrant treatment and (d) renal biopsy is indicated in order to guide the treatment and give a better prediction of outcome. (e) Patients with rapidly progressive glomerulonephritis deserve aggressive intervention so as to halt the progression of renal damage and subsequent renal failure. Corticosteroid in combination with immunosuppressive agents is the commonly used treatment option and plasmapheresis could be an adjuvant therapy.